EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Multi-omics analysis reveals cuproptosis and mitochondria-based signature for assessing prognosis and immune landscape in osteosarcoma

Chenguang Jia, Mei Liu, Liming Yao, Fangchao Zhao, Shuren Liu, Zhuo Li, Yongtai Han

Frontiers in Immunology · 2024

DOI: 10.3389/fimmu.2023.1280945 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Immunology, 2024. Verfasst von Chenguang Jia und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Osteonecrosis and Hip Surgery, The Third Hospital of Hebei Medical University, Shijiazhuang, China. Hauptthemen laut MEDLINE: Osteosarcoma, Bone Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Osteosarcoma (OSA), the most common primary mesenchymal bone tumor, is a health threat to children and adolescents with a dismal prognosis. While cuproptosis and mitochondria dysfunction have been demonstrated to exert a crucial role in tumor progression and development, the mechanisms by which they are regulated in OSA still await clarification.

Methods

Two independent OSA cohorts containing transcriptome data and clinical information were collected from public databases. The heterogeneity of OSA were evaluated by single cell RNA (scRNA) analysis. To identify a newly molecular subtype, unsupervised consensus clustering was conducted. Cox relevant regression methods were utilized to establish a prognostic gene signature. Wet lab experiments were performed to confirm the effect of model gene in OSA cells.

Results

We determined 30 distinct cell clusters and assessed OSA heterogeneity and stemness scRNA analysis. Then, univariate Cox analysis identified 24 candidate genes which were greatly associated with the prognosis of OSA. Based on these prognostic genes, we obtained two molecular subgroups. After conducting step Cox regression, three model genes were selected to construct a signature showing a favorable performance to forecast clinical outcome. Our proposed signature could also evaluate the response to chemotherapy and immunotherapy of OSA cases.

Conclusion

We generated a novel risk model based on cuproptosis and mitochondria-related genes in OSA with powerful predictive ability in prognosis and immune landscape.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteosarcomaBone NeoplasmsAdolescentChildHumansMultiomicsMitochondriaPrognosisDNA, MitochondrialRNA

Stichwörter der Autor:innen

cuproptosismitochondria dysfunctionosteosarcomaprognostic biomarker heterogeneitystemness

Substanzen

DNA, MitochondrialRNA

Autor:innen und Institutionen

  • Department of Osteonecrosis and Hip Surgery, The Third Hospital of Hebei Medical University, Shijiazhuang, China.
  • Department of Orthopedics, Hebei Chest Hospital, Shijiazhuang, China.
  • Molecular Biology Laboratory, Hebei Chest Hospital, Shijiazhuang, China.
  • Department of Thoracic Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang, China.

Zitieren

APA

Jia, C., Liu, M., Yao, L., Zhao, F., Liu, S., Li, Z., & Han, Y. (2024). Multi-omics analysis reveals cuproptosis and mitochondria-based signature for assessing prognosis and immune landscape in osteosarcoma. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2023.1280945

Vancouver

Jia C, Liu M, Yao L, Zhao F, Liu S, Li Z, et al. Multi-omics analysis reveals cuproptosis and mitochondria-based signature for assessing prognosis and immune landscape in osteosarcoma. Frontiers in Immunology. 2024. doi:10.3389/fimmu.2023.1280945

BibTeX
@article{Jia2024,
  author = {Jia, Chenguang and Liu, Mei and Yao, Liming and Zhao, Fangchao and Liu, Shuren and Li, Zhuo and Han, Yongtai},
  title = {Multi-omics analysis reveals cuproptosis and mitochondria-based signature for assessing prognosis and immune landscape in osteosarcoma},
  journal = {Frontiers in Immunology},
  year = {2024},
  doi = {10.3389/fimmu.2023.1280945}
}
Kostenlos starten →